Leukemia in children treated with growth hormone

Area of Science:

• Pediatric Endocrinology
• Hematology-Oncology
• Clinical Research

Background:

• A historical association between growth hormone (GH) therapy and leukemia development was noted in 1988.
• This perceived link may stem from a higher prevalence of leukemia risk factors in children with GH deficiency (GHD).
• Identified risk factors include prior malignancies, cancer treatments, and genetic syndromes like Down, Bloom, and Fanconi syndromes.

Purpose of the Study:

• To investigate the association between GH treatment and leukemia incidence.
• To determine if underlying risk factors in children with GHD explain the observed leukemia rates.
• To assess leukemia risk in GH-treated individuals without predisposing conditions.

Main Methods:

• Analysis of large-scale databases containing information on individuals treated with GH.
• Comparison of leukemia incidence in GH-treated patients with and without known risk factors.
• Epidemiological review of patient cohorts.

Main Results:

• GH-treated patients without specific leukemia risk factors do not exhibit an increased incidence of leukemia.
• The higher rate of leukemia in some GH-treated populations is attributable to pre-existing risk factors.
• No causal link between GH therapy and leukemia development was established in the absence of risk factors.

Conclusions:

• The previously described association between GH treatment and leukemia is likely confounded by underlying risk factors in children with GHD.
• GH therapy itself does not appear to increase leukemia risk in children lacking predisposing conditions.
• This study clarifies the safety profile of GH treatment regarding leukemia development.